All PlansBilling CodesHigh impact
Metabolic monitoring for patients on antipsychotic medications
Harvard Pilgrim Health Care·Psychiatry, Family Medicine, Internal Medicine +2 more·Provider Newsletter
We identified it
Sep 8, 2026
Summary
Point32Health issued a metabolic monitoring policy for patients on antipsychotic medications, emphasizing annual screening for diabetes and cholesterol levels. The policy provides approved CPT codes for billing glucose, HbA1c, LDL-C, and other cholesterol tests, and requires providers to document baseline metabolic testing at discharge and coordinate care across behavioral health, primary care, and prescribing providers.
Action Required
Immediately: Billing team must ensure all metabolic screening claims for antipsychotic patients use ONLY the approved CPT codes listed in the policy. Update billing system validation rules to enforce correct code usage for glucose (80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951), HbA1c (83036, 83037), LDL-C (80061, 83700, 83701, 83704, 83721), and other cholesterol tests (82465, 83718, 84478, 83722). Coordinate with providers and clinical staff to ensure: (1) metabolic testing is ordered at antipsychotic initiation and annually thereafter for all patients on these medications; (2) baseline blood glucose levels are documented on inpatient discharge plans; (3) discharge paperwork with metabolic testing instructions is shared with PCP, prescriber, and community providers. Update encounter forms and EMR templates to prompt providers to document metabolic monitoring orders and results. Train front-desk and clinical staff to verify that patients on antipsychotics have metabolic screening documented before follow-up appointments. Failure to use approved codes may result in claim denials or payment adjustments.